Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
GSK945237 · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| GSK945237 | EXPERIMENTAL | Active Study Drug |
| Sugar Pill | PLACEBO_COMPARATOR | Placebo |
| Name | Type | Description |
|---|---|---|
| GSK945237 | DRUG | - |
| Sugar Pill | DRUG | Placebo |
Inclusion Criteria: * Healthy male and female adults between 18 and 60 years of age. * Body weight proportional to height. * Female subjects must be of non-childbearing potential. * QTc less than 450 msec at screening Exclusion Criteria: * Any clinically relevant abnormality identified on the scr...
GSK945237 is an investigational small molecule being studied for use in healthy subjects and for bacterial infections. It is in Phase 1 clinical development, and the completed trial evaluated the drug in healthy volunteers to assess safety, tolerability, pharmacokinetics, and the effect of food on single doses.
GSK945237 is being developed by GSK plc, a global biopharmaceutical company. GSK plc is listed on the stock exchange under the ticker symbol GSK.
GSK945237 is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The Phase 1 trial has been completed, and the drug is no longer in active clinical trials.
GSK945237 has one completed Phase 1 clinical trial, identified as NCT00517673. This trial evaluated the safety, tolerability, pharmacokinetics, and food effect of single doses of GSK945237 in healthy subjects. The trial enrolled 68 participants in Australia and was placebo-controlled.
GSK945237 is not FDA approved. It is an investigational drug that has completed a Phase 1 clinical trial in healthy subjects. The drug is still in clinical development and has not been approved for any use.